NFE2L2 and cancer: Cells with downregulated Nrf2 are more susceptible to pro-ferroptotic agents, whereas Nrf2 overexpression prevents both the initiation and execution of ferroptosis, supporting the Nrf2 regulatory network as a viable therapeutic target for managing ferroptosis-related diseases, including cancer and organ injury [116,118].